image credit- istock.com
The State Food and Drug Administration of China (CFDA) has conditionally approved the application for the listing of the Ganlut sodium capsule (trade name “Nine Phase One”) for mild to moderate Alzheimer's disease and improved cognitive function.
The drug is a low-molecular acidic oligosaccharide compound prepared by extracting marine brown algae as a raw material. It is an innovative drug independently researched and developed by China and possessing independent intellectual property rights. It has won major national special new drug creation technology and special support.
The pathogenesis of Alzheimer's disease is very complicated, the duration of the disease is long, and the cure is difficult. The listing of the drug will provide patients with new drug options.
The CFDA requires applicants to continue their research on pharmacological mechanisms and long-term safety effectiveness studies after listing, improve the analysis methods of oligosaccharides, and submit relevant test data on time.
